Aclimostat
Based on 1 Customer Validation
Aclimostat (ZGN-1061) is a methionine aminopeptidase 2 (MetAP2) inhibitor. Aclimostat exhibits anti-obesity, anti-diabetic and ovarian cancer-related activities, and does not readily distribute to the central nervous system. Aclimostat acts on the active site of MetAP2 via irreversible covalent binding, and blocks enzyme activity through interactions with His231 and His339. Aclimostat regulates gene expression, reduces fat mass, plasma glucose, insulin levels, LDL-C, hs-CRP and leptin levels, while increasing adiponectin levels. Aclimostat can be used in research related to type 2 diabetes, overweight, obesity and ovarian cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.0%
- No. CAS: 2082752-83-6
- Fòrmula: C26H42N2O6
- Peso molecular:478.62
-
Almacenamiento:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
|
MetAp2 |
In Vitro
Aclimostat (10 nM; 2 h, assessed over 72 h post-washout) shows transient target engagement in HUVECs, with covalent binding to the MetAP2 active site declining over 72 hours after a 2-hour 10 nM exposure, and no sustained accumulation of the MetAP2 substrate THX 1-6[2].
Aclimostat (10 nM; 2 h, assessed over 72 h post-washout) shows transient target engagement in HepG2 cells, with covalent binding to the MetAP2 active site declining over 72 hours after a 2-hour 10 nM exposure[2].
ZGN-1061 binds strongly to human MetAP2 with a docking score of -7.2 kcal/mol, interacting with key active site residues critical for MetAP2 function[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HUVEC (human umbilical vein endothelial cell)
-
Concentration:1 nM, 10 nM, 20 nM
-
Incubation Time:4 h; 8 h; 72 h
-
Result:Did not alter p53 or von Willebrand factor (vWF) protein levels at any concentration or incubation time.
Increased p21 and reduced thrombomodulin (TM) protein levels at all concentrations after 72-hour incubation.
Showed no meaningful changes in p21 and TM protein levels with 4-hour or 8-hour incubations.
Had no effect on plasminogen activator inhibitor-1 (PAI-1) protein levels at any concentration or time point.
-
Cell Line:A2780 ovarian cancer cells (control and METAP2-knockdown), SKOV3 ovarian cancer cells (control and METAP2-overexpressing)
-
Concentration:0-5000 nM
-
Incubation Time:1-6 days
-
Result:Significantly inhibited proliferation in control A2780 cells.
Showed attenuated inhibitory effect in METAP2-knockdown A2780 cells.
Exhibited enhanced anti-proliferative activity in METAP2-overexpressing SKOV3 cells compared to control SKOV3 cells.
Reduced IC50 values in METAP2-overexpressing SKOV3 cells relative to control SKOV3 cells.
In Vivo
ZGN-1061 (s.c.; daily; 28 days) reduces body weight by 25% and improves glucose and insulin levels in diet-induced obese insulin-resistant mice[5].
Aclimostat (2-25 mg/kg; s.c.; every 3 days; 28 days) is well tolerated in Sprague Dawley rats, with minimal, reversible toxic effects[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 7 to 8 weeks old at study start, high-fat diet-induced obese model)[2]
-
Dosage:0.3 mg/kg
-
Administration:s.c.; daily; 4 weeks
-
Result:Reduced body weight by 25%, primarily due to reduced fat mass.
Significantly increased percent lean mass relative to vehicle at Weeks 2 and 4.
Reduced mean daily energy intake to 0.35 kJ/g lean mass at Week 2, comparable to vehicle levels by Week 4.
Improved fasting glucose and insulin levels, with a statistically significant reduction in HOMA-IR index relative to vehicle.
Produced statistically significant reductions in low-density and high-density lipoprotein cholesterol, alongside increased β-hydroxybutyrate levels and reduced leptin levels.
Increased target engagement (measured by N-terminal methionine of thioredoxin [THX 1-6]) from below the limit of detection to a level comparable to beloranib.
-
Animal Model:Beagle (male, 10 to 20 months old)[2]
-
Dosage:2 mg/kg
-
Administration:s.c.; every 3 days; 10 days
-
Result:Produced no adverse changes in clinical observations, hematology (including platelet count), or coagulation markers (D-dimer, thrombin time, antithrombin III).
Caused weight loss over the study period, but food intake remained unchanged, and all animals survived the scheduled dosing period.
-
Animal Model:Sprague Dawley (male and female, 9−10 weeks old)[2]
-
Dosage:2 mg/kg; 6 mg/kg; 25 mg/kg
-
Administration:s.c.; every 3 days; 28 days
-
Result:Observed no mortality at any dose tested.
Showed the highest dose (25 mg/kg) was well tolerated, with increased injection site irritation and inflammation that largely resolved after the 10-week recovery period (minimal fibrosis noted in 3/10 rats).
Produced minimal, low-incidence findings including mixed cell inflammation in the lung and individual hepatocellular necrosis, which resolved after dosing ceased.
At the no observed adverse effect level (NOAEL), produced repeat-dose AUC0-t values of 409 ng×h/mL (males) and 288 ng×h/mL (females), with Cₘₐₓ values 21- to 52-fold higher than beloranib at its respective NOAEL.
-
Animal Model:BALB/c nude (female)[3]
-
Dosage:0.1 mg/kg
-
Administration:s.c.; every 3 days; 4 weeks
-
Result:Markedly suppressed tumor progression, with significantly greater efficacy observed in METAP2-overexpressing xenografts.
Showed significantly higher tumor weight inhibition in METAP2-overexpressing xenografts compared to control xenografts.
Was well-tolerated with no significant body weight changes or signs of toxicity.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 2082752-83-6
-
Appearance Solid
-
Peso molecular 478.62
-
Fòrmula C26H42N2O6
-
Color White to off-white
-
SMILES
C[C@]1([C@H](O1)C/C=C(C)\C)[C@]2([H])[C@]3(CC[C@H]([C@H]2OC)OC(N4CC(C4)CCN5CCOCC5)=O)CO3
-
Synonyms
ZGN-1061
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvente y solubilidad
In Vitro:
DMSO : 230 mg/mL (480.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (294 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Wentworth JM, et al. The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes, obesity & metabolism. 2020 Jul;22(7):1215-1219. [Content Brief]
[2]. Burkey BF, et al. Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061. J Pharmacol Exp Ther. 2018 May;365(2):301-313. [Content Brief]
[3]. Wu L, et al. METAP2 inhibits K48-linked ubiquitination of YTHDF2 to promote ovarian cancer progression. Oncogene. 2025 Dec;44(46):4505-4519. [Content Brief]
[4]. Malloy J, et al. Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial. Diabetes, obesity & metabolism. 2018 Aug;20(8):1878-1884. [Content Brief]
[5]. Moon DO, et al. MetAP2 as a Therapeutic Target for Obesity and Type 2 Diabetes: Structural Insights, Mechanistic Roles, and Inhibitor Development. Biomolecules. 2024 Dec 10;14(12):1572. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0893 mL | 10.4467 mL | 20.8934 mL | 52.2335 mL |
| 5 mM | 0.4179 mL | 2.0893 mL | 4.1787 mL | 10.4467 mL | |
| 10 mM | 0.2089 mL | 1.0447 mL | 2.0893 mL | 5.2234 mL | |
| 15 mM | 0.1393 mL | 0.6964 mL | 1.3929 mL | 3.4822 mL | |
| 20 mM | 0.1045 mL | 0.5223 mL | 1.0447 mL | 2.6117 mL | |
| 25 mM | 0.0836 mL | 0.4179 mL | 0.8357 mL | 2.0893 mL | |
| 30 mM | 0.0696 mL | 0.3482 mL | 0.6964 mL | 1.7411 mL | |
| 40 mM | 0.0522 mL | 0.2612 mL | 0.5223 mL | 1.3058 mL | |
| 50 mM | 0.0418 mL | 0.2089 mL | 0.4179 mL | 1.0447 mL | |
| 60 mM | 0.0348 mL | 0.1741 mL | 0.3482 mL | 0.8706 mL | |
| 80 mM | 0.0261 mL | 0.1306 mL | 0.2612 mL | 0.6529 mL | |
| 100 mM | 0.0209 mL | 0.1045 mL | 0.2089 mL | 0.5223 mL |
Aclimostat Related Classifications
HY-114196 Related Classifications
Powered by Bioz